title: How will we manage acute HCV in men having sex with men in the era of all oral therapy?
abstract: With the advent of direct-acting antivirals (DAAs), the treatment of chronic hepatitis C virus (HCV) infection (CHC) has been revolutionized. Modern interferon- and potentially also ribavirin-free combinations consisting of 2 or 3 direct-acting antivirals (DAA) promise sustained virological response rates (SVR) of above 90%. This coincides with much shorter treatment durations and a much more favorable toxicity profile. Some DAAs even work across all HCV genotypes (pangenotypic) [BMJ, 349, 2014, g3308]. And lastly, HCV treatment in HIV-coinfected patients will no longer differ from HCV-monoinfected patients as response rates under DAA in the setting of HCV-HIV coinfection have been as good as in HCV-monoinfected patients [J Hepatol, 61, 2014, 373]. Only drug-drug interactions with the new DAAs and concomitant antiretroviral therapy have to be accounted for due to shared metabolization pathways via the cytochrome p450 system.
authors.affiliation: Department of Internal Medicine I, Bonn University Hospital, Bonn, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Boesecke
authors.forename: J K
authors.initials: JK
authors.lastname: Rockstroh
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004347:Drug Interactions; D006526:Hepatitis C / Q000175:diagnosis* / Q000188:drug therapy*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male
chemical_list: D000998:Antiviral Agents
keywords: Acute hepatitis C; DAA; HIV; MSM